In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 26, 2019
Novartis Appoints New Sandoz CEO
Author(s)BioPharm International Editors
Sandoz’s new CEO will assume responsibilities no later than Aug. 1, 2019.
Advertisement
On April 24, 2019, Novartis announced the appointment of Richard Saynor as CEO of Sandoz effective no later than Aug. 1, 2019. He will be a member of Novartis’ executive committee and report to Vas Narasimhan, CEO, Novartis.
Saynor, currently senior vice-president of classic and established products, commercial and digital platforms at GlaxoSmithKline (GSK), has more than 20 years of global leadership experience spanning both generics and established pharmaceutical brands. He currently manages a $10-billion established products portfolio, which comprises over 350 brands commercialized in over 120 countries. In addition, Richard oversees the commercial digital platforms across all of GSK's pharmaceutical franchises.
Prior to GSK, Richard held commercial operations leadership roles at Sandoz and oversaw an expansion of Sandoz' generics business across Asia, Latin America, and Turkey. Richard is a pharmacist by training and started his pharma business career as a sales representative at pharmaceutical company G.D. Searle in the United Kingdom.
In
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5